Edwards Lifesciences (NYSE:EW) issued an update on its FY20 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $6.05-6.30 for the period, compared to the Thomson Reuters consensus estimate of $5.98. The company issued revenue guidance of $4.5-5.0 billion, compared to the consensus revenue estimate of $4.70 billion.Edwards Lifesciences also updated its FY19 guidance to $5.50-5.65 EPS.
NYSE EW traded down $3.67 on Thursday, reaching $242.52. 49,129 shares of the company’s stock traded hands, compared to its average volume of 1,217,416. The stock has a market cap of $51.35 billion, a PE ratio of 51.58, a P/E/G ratio of 2.96 and a beta of 0.80. Edwards Lifesciences has a 12 month low of $139.64 and a 12 month high of $247.64. The stock has a 50-day simple moving average of $237.19 and a 200 day simple moving average of $211.39. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.53 and a quick ratio of 2.74.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.19. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the prior year, the company earned $1.07 EPS. The firm’s revenue was up 20.7% on a year-over-year basis. As a group, analysts anticipate that Edwards Lifesciences will post 5.6 EPS for the current year.
EW has been the subject of several analyst reports. Cowen upped their price target on shares of Edwards Lifesciences from $250.00 to $265.00 and gave the company a positive rating in a research report on Thursday, October 24th. Canaccord Genuity lifted their price objective on Edwards Lifesciences from $250.00 to $260.00 and gave the stock a buy rating in a report on Thursday, October 24th. Jefferies Financial Group boosted their target price on Edwards Lifesciences from $255.00 to $285.00 and gave the company a buy rating in a research note on Tuesday. Raymond James increased their target price on Edwards Lifesciences from $250.00 to $255.00 and gave the company an outperform rating in a report on Thursday, October 24th. Finally, Royal Bank of Canada raised their price target on Edwards Lifesciences from $217.00 to $250.00 and gave the stock an outperform rating in a research report on Tuesday, October 22nd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $231.94.
In other Edwards Lifesciences news, VP Catherine M. Szyman sold 2,500 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $242.14, for a total transaction of $605,350.00. Following the transaction, the vice president now directly owns 19,605 shares of the company’s stock, valued at approximately $4,747,154.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 7,500 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $225.74, for a total transaction of $1,693,050.00. Following the completion of the transaction, the chief financial officer now owns 21,064 shares of the company’s stock, valued at $4,754,987.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 126,651 shares of company stock worth $29,299,139. 1.63% of the stock is owned by company insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Story: What does an outperform rating mean?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.